Insider Selling: Revolution Medicines (NASDAQ:RVMD) CFO Sells 2,753 Shares of Stock

Key Points

• CFO Jack Anders sold 2,753 shares on March 17 at an average price of $99.48 for $273,868, reducing his stake by 2.15% to 125,512 shares; he also sold 10,000 shares on Jan. 7 at $98.00.
• RVMD stock is trading near $99.29 with a $19.68 billion market cap and negative EPS, while analysts maintain a consensus "Buy" rating with an average target price of $78.94—below the current price.

Revolution Medicines, Inc. (NASDAQ:RVMD - Get Free Report) CFO Jack Anders sold 2,753 shares of Revolution Medicines stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $99.48, for a total transaction of $273,868.44. Following the completion of the sale, the chief financial officer owned 125,512 shares in the company, valued at approximately $12,485,933.76. This represents a 2.15% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Jack Anders also recently made the following trade(s):

• On Wednesday, January 7th, Jack Anders sold 10,000 shares of Revolution Medicines stock. The shares were sold at an average price of $98.00, for a total value of $980,000.00.

Revolution Medicines Price Performance

RVMD stock traded up $1.18 on Thursday, hitting $99.29. 1,485,201 shares of the company's stock traded hands, compared to its average volume of 2,335,170. The stock has a market cap of $19.68 billion, a price-to-earnings ratio of -16.80 and a beta of 0.99. Revolution Medicines, Inc. has a 1-year low of $29.17 and a 1-year high of $124.49. The stock has a fifty day moving average of $103.58 and a 200-day moving average of $76.24. The company has a current ratio of 7.14, a quick ratio of 7.14 and a debt-to-equity ratio of 0.16.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last posted its quarterly earnings results on Wednesday, February 25th. The company reported ($1.86) earnings per share for the quarter, missing analysts' consensus estimates of ($1.56) by ($0.30). During the same period last year, the business earned ($1.12) EPS. On average, analysts forecast that Revolution Medicines, Inc. will post -3.49 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Indiana Trust & Investment Management Co bought a new position in Revolution Medicines in the 4th quarter valued at about $32,000. Global Retirement Partners LLC boosted its holdings in shares of Revolution Medicines by 1,002.8% during the fourth quarter. Global Retirement Partners LLC now owns 397 shares of the company's stock worth $32,000 after acquiring an additional 361 shares during the period. Torren Management LLC acquired a new position in shares of Revolution Medicines in the fourth quarter valued at approximately $33,000. Arax Advisory Partners acquired a new position in shares of Revolution Medicines in the fourth quarter valued at approximately $38,000. Finally, GAMMA Investing LLC grew its holdings in Revolution Medicines by 45.1% in the 3rd quarter. GAMMA Investing LLC now owns 837 shares of the company's stock valued at $39,000 after buying an additional 260 shares in the last quarter. 94.34% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

RVMD has been the subject of a number of recent research reports. Evercore upgraded Revolution Medicines to a "strong-buy" rating in a research report on Wednesday, February 25th. Jefferies Financial Group began coverage on shares of Revolution Medicines in a report on Monday. They issued a "buy" rating on the stock. UBS Group assumed coverage on shares of Revolution Medicines in a report on Friday, February 27th. They set a "buy" rating for the company. Wedbush reiterated an "outperform" rating on shares of Revolution Medicines in a research report on Friday, January 9th. Finally, Benchmark reiterated an "overweight" rating on shares of Revolution Medicines in a report on Tuesday, February 17th. Four research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $78.94.

About Revolution Medicines

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company's research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.